Clinical Trials Browser

Uterine Cervical Neoplasms × sacituzumab govitecan × 1 year × Clear all

NCT05838521 2026-02-06

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms